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ABSTRACT 
 
Background: New curative treatments for hepatitis C have the potential to alter the 
course of a devastating epidemic. High drug prices, however, are widely believed to 
contribute to restrictions on treatment access. We aimed to learn how state health 
agencies have responded to the challenges of treatment access for HCV 
Methods: Using a key informant interview design, we interviewed 14 health officials and 
4 treatment advocates in six states. States were chosen using purposive sampling 
based on diverse geography, population size, known HCV treatment eligibility criteria 
and Medicaid expansion status. Interviews were semi-structured with questions that 
focused on aspects of HCV treatment access. We used content analysis to analyze 
transcripts for dominant themes. 
Results: Treatment cost was the most significant barrier to expanding access and 
acted by directly influencing payers to restrict access, as well as creating the impression 
among guideline committees and providers that HCV treatment needed to be prioritized. 
Treatment eligibility criteria from state Medicaid programs did not necessarily reflect the 
actions of managed care organizations, who could be more variable. Additional barriers 
to access included stigma around HCV and substance use, as well as provider 
availability, especially in rural areas. The political and fiscal environment within states 
could aid or hinder treatment access, and evolving federal health policy surrounding 
Medicaid evoked concern that funding for HCV treatment access could be diminished. 
Individuals co-infected with HIV and HCV had additional mechanisms to access 
treatment.  
Conclusions: While treatment eligibility criteria for HCV treatment are improving, a 
number of other barriers remain to achieving the scale-up needed to end the epidemic. 
Further work to mitigate the effects of stigma and build treatment capacity will be 
needed. The effects of federal health policy changes on Medicaid funding may impact 
states’ ability to respond to this epidemic. 
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Introduction:  
Hepatitis C virus (HCV) infection affects an estimated 5 million Americans.1, 2 It is 
a leading infectious killer, and since 2007 has killed more Americans annually than 
HIV.3 While the majority of HCV is concentrated in the ‘baby boomer’ generation,4 
recent increases in opioid use have led to emerging epidemics in younger persons who 
inject drugs.5, 6 Hepatitis C has a long asymptomatic period that typically lasts many 
years, allowing for ongoing transmission and the development of severe liver disease. 
Indeed, hepatitis C is a leading cause of hospitalization due to liver disease and liver 
transplantation in the United States.7, 8 Coinfection with HCV and HIV has a worse 
prognosis than HCV mono-infection with faster rates of liver fibrosis, in patients with 
poorly controlled HIV.9 
Since 2014, new classes of medications called direct acting antivirals (DAAs) 
have been available as treatment for HCV. DAA regimens are highly effective, with cure 
rates consistently over 90%, and have largely replaced prior treatments.10 Treatment of 
HCV is cost-effective from a societal perspective, preventing the morbidity and mortality 
associated with cirrhosis and liver transplantation.11-17 Modeling studies have suggested 
that scale up of DAA treatment may prevent transmission and has the potential to end 
the epidemic.18-20 The path to eliminating HCV requires improved diagnosis, linkage to 
care, and treatment uptake will be needed, especially for persons who inject drugs.21 
Despite their potential for reducing the epidemic burden, HCV DAAs have also 
received negative attention from activists, media, and the healthcare sector for their 
high cost. With early prices approaching $84,000 per treatment course,22 DAAs have 
been at the forefront of national dialogue on rising prescription drug costs. Anticipation 
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of these costs led state Medicaid programs to institute criteria limiting treatment to those 
with severe disease, abstinence from substance use, a subspecialist provider, and 
suppressed HIV viral loads.23, 24 In 2014, the National Association of Medicaid Directors 
wrote to Congress requesting a federal response to HCV drug costs, citing the response 
to HIV/AIDS as an example.25 In 2015, Centers for Medicare and Medicaid Services 
(CMS) instructed Medicaid programs to improve treatment access and lift treatment 
restrictions.26 Judicial decisions in Washington State and elsewhere have also largely 
supported expanded treatment access.27 The states’ responses to the challenge of 
providing coverage for DAAs have varied, and the factors that have influenced policy 
change remain unknown.  
To determine state level factors affecting DAA treatment expansion, we 
interviewed state health officials and treatment advocates with expertise in HCV 
treatment. Hypothesizing that the HIV/HCV coinfected individuals may have additional 
coverage options, we also interviewed experts in HCV treatment coverage for this 
subpopulation. We chose to conduct these interviews in 6 states that represent diverse 
policy environments. 
Methods:  
 We conducted key informant interviews with experts in HCV treatment access in 
the United States from June 2016 to March 2017. Study methods and findings are 
reported using elements of COREQ criteria for reporting qualitative research.28 
Research Team 
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The research team consisted of two physicians with experience in HCV 
treatment, (S.K. and C.J.) and two health policy researchers with qualitative research 
experience and expertise in federal and state policies for HIV treatment (E.M. and B.S.). 
All interviews were conducted by one investigator (S.K.). Data analysis was performed 
by three investigators. (S.K., C.J., E.M.) All four investigators met regularly to interpret 
data and discuss themes.  
Participant Recruitment 
We used purposeful sampling to select six states of interest based on purposeful 
sampling,29 aiming for diverse geography, total population sizes, Medicaid expansion 
status, and published treatment eligibility criteria for HCV DAA coverage.23, 24, 30 For 
each state, we identified up to three health officials with complementary expertise in 
how HCV treatment is publically financed. We also identified experts from treatment 
advocacy organizations and federal programs to gain a national perspective. 
Candidates were identified first using internet search, and then using recommendations 
from contacts in each state. Candidates who declined to interview were asked to identify 
other potential experts for interview. Additional states, and participants within them, 
were added to the study until theoretical saturation, when no new themes emerged from 
further data collection.29 We approached 24 potential candidates: 18 agreed to be 
interviewed, 4 declined to be interviewed due to lack of expertise but provided referral to 
other potential candidates, and 2 declined to be interviewed and did not provide 
additional referrals. Table 1 displays characteristics of states and participants. Because 
of a desire for anonymity from respondents who were state employees, individual state 
names and respondent names or specific job titles are not reported.  
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Table 1: 
 Number 
of 
interviews 
States Included in Study  
State 1: Northeast region, Medicaid expansion, no severity criteria, no substance use 
criteria 
2 
State 2: West region, Medicaid expansion, lenient severity criteria (F2), no substance use 
criteria 
2 
State 3: South region, no Medicaid expansion, lenient severity criteria (F2), no substance 
use criteria 
3 
State 4: South region, no Medicaid expansion, no severity criteria, need for documented 
substance use abstinence.  
1 
State 5: Northeast region, Medicaid expansion, no severity criteria, no substance use 
criteria  
3 
State 6: Midwest region, Medicaid expansion, strict severity criteria (F3), need for 
documented substance use abstinence 
3 
  
Professional Role of Key informants  
Public Health Official – HCV Focus 5 
Public Health Official – HIV/AIDS Focus 6 
Public Health Official – Other 4 
Advocacy or professional organization member 3 
 
Data Collection 
We used a semi-structured interview guide that focused on mechanisms that 
facilitated hepatitis C treatment, barriers to hepatitis C treatment, the contrast between 
treatment access for persons co-infected with HIV and HCV versus persons mono-
infected with HCV, specific treatment eligibility criteria in state Medicaid programs, and 
expectations regarding future HCV treatment access. Interviews were conducted over 
the telephone by one investigator (S.K.) and lasted approximately 1 hour. Interviews 
were digitally recorded and transcribed for analysis using a commercial transcription 
service. In order to triangulate findings, we reviewed published literature on Medicaid 
and ADAP treatment criteria, and publicly available government documents regarding 
HCV treatment coverage in the selected jurisdictions. A copy of the interview guide is 
included in the appendix.  
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Data Analysis 
De-identified transcripts were coded using content analysis.31 A codebook was 
developed based on the first 4 transcripts and updated iteratively with each new 
transcript.32 Two investigators (S.K., C.J.) coded all transcripts independently, and 
discrepancies in coding were resolved in in-person meetings. A subset of transcripts 
were independently coded by E.M. to refine codebook development. Codes were 
analyzed for themes during monthly in-person discussions by the research team. All 
data were coded in NVivo Software (QST International Pty Ltd., Version 11).  Code 
labels and descriptions are included in the appendix. 
Results:  
Treatment cost triggers multiple barriers to expanding HCV treatment coverage  
Every respondent identified the importance of high treatment cost as the most 
significant barrier to treatment. High initial costs when DAAs came onto market in 2014 
spurred payers to limit access to treatment: “Cost concerns were just so 
overwhelming…and state Medicaid programs… had not budgeted for these drugs and 
were just grappling with how they could make access a reality. [Professional 
organization member]” One respondent was “surprised that our Medicaid initially 
resisted to [provide] comprehensive coverage for the HCV medications…of course, it 
was primarily cost driven. [Health official, state 6]” In some states, high cost for DAA 
treatment reduced enthusiasm within health agencies for prioritizing HCV treatment, A 
state Medicaid official stated that “there’s so many other populations of people that are 
bigger than that who also need [treatment]…Can’t help everybody. [Health official, State 
3]”  
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The publicity around treatment cost created an early impression among clinical 
societies, policymakers, and providers that access to HCV therapy could be prioritized 
to those with severe disease, an idea that was incorporated into early iterations of 
national treatment guidelines and influenced the criteria that payers developed: “The 
national guidelines didn't really do us any favors…when they came out with that list of 
priorities, it was pretty much the nail on the coffin” [Health Official, NY].  In 2014, most 
state Medicaid programs had imposed eligibility criteria to restrict treatment access 
based on these priorities: such as requiring high disease severity, proof of abstinence 
from substance use, and a specialist treating provider. One respondent attributed these 
criteria to “rationing, because [payers] feel like they need to contain cost.” Respondents 
from every state indicated that criteria based on disease severity, which began by 
requiring advanced fibrosis in many states, are generally becoming less restrictive, but 
this was not universally the case for other criteria. The feeling that access needs to be 
limited to save cost may also affect provider willingness to treat HCV: one health official 
that surveyed local providers reported that: “Everybody is so distracted by what’s in the 
media that they don’t look at anything else…So many providers had said to us, ‘We’re 
so afraid to begin to start somebody on treatment because it’s so expensive.’ [Health 
official, State 5]” Even as payers are relaxing treatment eligibility criteria in order to 
cover treatment, providers may be informally adapting similar criteria in the office setting 
to determine a patient’s readiness for treatment, limiting the impact of more lenient 
policies. 
All respondents expressed frustration about the lack of transparency in drug 
pricing and treatment utilization, which hampered efforts to improve access. Health 
officials in five states described difficulties accessing information on treatment coverage 
and drug prices from private payers and other governmental agencies. This lack of 
transparency “made it hard to hold any party accountable, and that makes it difficult for 
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the work of advocates or providers or patients.” One respondent was “frustrated by the 
lack of information…the media is very quick to jump on a $1,000 a pill headline…but 
there’s also been a lack of nuance about the fact that the wholesale acquisition cost for 
drugs is not actually what anybody pays. [Treatment advocate]” On the other hand, 
another respondent noted the potential benefit of some degree of secrecy: “many of the 
states where you have seen changes in the last year, part of the motivation for those 
changes has been behind the scenes negotiations with the drug companies to get more 
favorable rebate agreements.” 
 Despite the strong uniform concern about the impact of cost on treatment 
access, the effect on payers may be less severe than initially feared. A public health 
official stated that “if everyone had presented for care simultaneously and we had paid 
full price for those drugs, it would have broken the bank for Medicaid and even strained 
the ability of our HIV drug assistance program to keep up…neither one of those was a 
reality. [Health official, State 5]” Respondents described several factors that mitigated 
the impact of high drug costs on payers: the medical eligibility restrictions that payers 
used to limit treatment access were effective in doing so; newer medications have 
brought competition to the marketplace and thus lower prices; and some state 
governments have offered additional payments to insurance plans to motivate HCV 
treatment.  
Treatment eligibility criteria changes by fee-for-service Medicaid do not necessarily 
apply to managed care 
Even as fee for service Medicaid criteria have improved, respondents in four 
states discussed the continued variability in the practices of Medicaid managed care 
organizations. “The policy gets operationalized by…managed care plans…and they 
each operationalize the policy in their own way. Some…err on the side of approval and 
some err on the side of being very conservative and denying many requests. [Treatment 
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advocate]” While managed care is required to be as or more lenient than the state fee-
for-service program, this requirement is not universally enforced: “it’s very clear in the 
law that Medicaid managed care plans cannot use criteria that are more restrictive than 
the fee for service standard. Now, that doesn’t always mean that all states follow that 
law…I think even where the state has been pretty clear with the managed care plans 
that they must follow the standard in fee-for-service or something more generous, the 
managed care plans to some extent do what they want to do and it’s tough for the state 
to go around and enforce its standards against every managed care plan. [Professional 
organization]” 
An official in another state was frustrated by the effect of this variability on 
providers: “I had my providers develop a spreadsheet looking at all the various plans…It 
was all over the place in terms of what the requirements were. That takes away from 
direct patient care. [Health official, State 1]” The complexity of the prior authorization 
process serves to discourage providers from offering HCV treatment and allows payers 
a way to “insert cogs into the machine [Health official, State 2]” For example, one plan 
“has things that seem like almost blatant obfuscation, like fax numbers where you send 
your prior auth and then they say they never received it. [Treatment advocate]” These 
processes, while not as explicit as eligibility restrictions described above, can “take 
hours on the phone…on hold…and filling out endless paperwork just to get the drug 
approved…It’s a hidden cost of this work. I think those are being used even with open 
access, to restrict the flood, to dam up the demand a little bit and make it trickle a little 
bit more [Health official, State 5].” 
Stigma, patient engagement, and provider availability are additional barriers to 
treatment access 
Beyond cost and coverage policies, respondents in all states identified stigma 
around HCV and injection drug use as a second major barrier to HCV treatment access 
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that affected policymaking, providers, and patients alike. Stigma was “underlying 
everything we see, because while treatment is certainly very expensive, when you look 
at it compared to treatments for other big infectious diseases or big diseases in general, 
it’s not that much different. But I think because it’s a disease that predominantly impacts 
low-income people, people of color, people who are drug users, the perception is very, 
very different. [Professional organization]” Respondents with experience in HIV 
contrasted the strong political and advocacy movement surrounding HIV with the 
current environment in HCV, where affected populations have limited political voice. 
Stigma may also affect provider willingness to screen and treat HCV: “There are a lot of 
providers out there that don’t want to screen for hep-C because they think they’re going 
to bring in this flood of people who are drug users, and they don’t want to take care of 
those individuals. [Health Official, State 1]”  
The third major perceived barrier to widespread HCV treatment access is 
patients’ and providers’ reluctance to initiate treatment due to a perceived lack of 
urgency and negative experiences with older treatments. Because HCV has a long 
asymptomatic latency period before affecting health outcomes, linking HCV patients to 
treatment is not perceived to be “as urgent as it feels with some other diseases, notably 
HIV. [Health official, State 5]” One respondent described “a little bit of a hangover from 
when the treatment regimens were more complicated, more toxic and less effective, so 
providers are a little bit slow to change their practice. [Health official, State 5]” Another 
described a similar effect for patients: “people with hepatitis C infections got such a 
negative image of hepatitis C treatment based on the pretty horrific experiences of the 
interferon treatments and their low efficacy that we didn’t see people banging down the 
doors at the very beginning. [Health official, State 5]”  
Respondents in every state perceived a shortage of providers who were qualified 
to treat HCV, although this concern was highest in states with large rural HCV 
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populations. In two southern states, teaching hospitals were the most common places to 
receive HCV treatment, but these hospitals did not cover a wide geographic area. One 
public health official noticed “If you’re not…where there’re a lot of providers—and 
there’s an awful lot of rural [areas]--you’re not going to be travelling…to the doctor 
unless you’re almost dead. [Health official, State 4]” In one Midwestern state, a large 
area “has really poor access to specialty care and very poor access to…medication 
therapy, substance use disorder, and even primary care is tough. [Health official, State 
6]” States have responded to this in two ways: some states have attempted to lift 
requirements that the prescribing provider be a subspecialist, and some have invested 
in programs to encourage primary care providers to treat HCV. Respondents in 3 states 
mentioned programs that offered telephone or electronic consultation for HCV 
treatment, and officials in one other state were hoping to implement such a program.  
An evolving political and fiscal environment can influence treatment access 
The political and fiscal environment, both federally and within the states, can help 
to either facilitate or hinder treatment access. In one southern state, a health official 
observed that federal support for HCV is insufficient to finance HCV treatment through 
public programs, and supplemental state support is limited due to competing priorities. 
In another state, fiscal difficulties diminished public health funds, impairing not only 
direct treatment coverage, but also the ability to fund innovative programs and provider 
outreach initiatives. Respondents in two states specifically credited their state’s political 
commitment to public health programs in aiding to promote HCV treatment access: 
“everyone in the administration recognized the importance of these drugs…[and that] 
the whole issue should be addressed equitably across all state payer sources. [Health 
official, State 2]”  
A number of factors dynamically affect the politics surrounding HCV treatment 
that may have influenced the behavior of state Medicaid programs and insurance plans. 
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Media and advocacy groups have criticized restrictive policies. While federal support 
has been lacking in some veins, the Centers for Medicare and Medicaid services did 
issue guidance that criticized restrictions as well.  Judicial decisions in several states 
have ruled against treatment restrictions, which has had the effect of motivating plans to 
improve treatment access: “states are getting to the point where they are worried that if 
somebody brings a lawsuit in the state, that they will have no choice but to make the 
change. So there are a few states that are trying to sort of get out ahead of that a little 
bit” [Professional Organization].  
Finally, the 2016 U.S. Presidential election and potential changes to or repeal of 
the Affordable Care Act is an important factor. In contrast to a primarily optimistic 
outlook in interviews conducted before the election, respondents who were interviewed 
after the election expressed concern: “I think it’ll be a worsening medical situation for 
people who can’t meet a covered group in Medicaid. A larger monetary burden on the 
Department of Health to help to cover people that either were terminated from Medicaid, 
couldn’t get coverage through their employer plan, had no insurance…” [Health Official, 
State 4]. Another respondent felt that the recent improvements made by their state in 
terms of treatment access might be at risk: “We are an expansion state. If that were to 
change, that would limit access to a lot of people where we just finally made a couple 
baby steps in getting people able to be treated” [Health Official, State 6]. 
Individuals coinfected with HIV and HCV have additional mechanisms to facilitate HCV 
treatment 
Although individuals coinfected with HIV/HCV are often more marginalized than 
HCV monoinfected individuals, they have better access to HCV treatment as a result of 
government programs for HIV care. AIDS Drug Assistance Programs (ADAPs) can 
facilitate treatment access by providing direct medication coverage for HIV and related 
conditions, purchasing insurance for enrollees, and paying copays and coinsurance. In 
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states without the Medicaid expansion, ADAP may cover HCV treatment for coinfected 
individuals who are not eligible for Medicaid, as income requirements for enrolling in 
ADAP are generally more lenient than they are for Medicaid. In every state we studied, 
ADAP’s requirements for approval of HCV medications were minimal compared to 
requirements of Medicaid programs, though this may not be representative of all state 
ADAP programs. As programs that primarily provide treatment coverage, ADAPs are 
generally “not able to cover…cost of lab testing and medical visits, [professional 
organization]” though some programs have launched initiatives to do so. While most 
states called ADAP a “payer of last resort,” allowing individuals to receive HCV therapy 
from ADAP if that therapy was denied through their primary insurance plan, one state 
program did not provide “gap coverage on a drug by drug basis. [Health official, state 5]” 
This variation can serve as a source of provider confusion which slows uptake: even in 
states where ADAPs covered HCV treatment, respondents indicated that providers 
were not always aware that ADAP programs could be used in this way. In addition to 
ADAP, HIV program infrastructure can provide additional services such as housing 
support, care coordination, and specially funded centers and health homes: these 
mechanisms can be used to either promote HCV treatment access directly, or to 
provide funding for innovative programs. 
Discussion:  
We interviewed experts in the HCV treatment landscape in the United States both 
nationally and within six states with diverse characteristics to understand barriers to 
DAA uptake and promising policy strategies. Our findings show that the cost of HCV 
therapy limits access by motivating payers to impose medical eligibility criteria and prior 
authorization requirements for treatment, in turn discouraging providers from offering 
treatment and patients from seeking it. The effects of costs on payers have been 
blunted by access limitations, and discounted prices due to negotiation and competition. 
 13  
This, in addition to legal and political pressure to provide treatment, has motivated fee-
for-service Medicaid programs to lighten eligibility criteria. However, managed care 
organizations can have a diverse set of authorization requirements even within the 
same state which can frustrate state officials and further discourage providers from 
offering treatment. Further, ADAP programs allow for additional coverage options for 
HIV/HCV coinfected individuals that are not available to HCV monoinfected. Beyond 
insurance coverage, other barriers to treatment access include stigma, patient and 
provider reluctance around treatment. Regional variation in access to providers and in 
political support and funding for HCV services limit the take-up in some regions.  
Our findings detail the mechanisms by which pricing hinders access: most 
significantly by driving payers to limit treatment access, but also by downstream 
administrative barriers such as prior authorization paperwork, which discourages 
providers from offering treatment. These findings are consistent with studies of prior 
authorizations and denials for HCV DAA, which find rates of denials up to 29% and long 
wait times before authorization decisions.33, 34 Treatment eligibility criteria, which have 
drawn criticism for being overly restrictive,35, 36 are improving for the fee-for-service 
Medicaid programs in the states that we studied. This improvement is consistent with 
findings from a report by the National Viral Hepatitis Roundtable in 2016, which found 
that compared to the findings in 2014, 14 fee-for-service Medicaid programs had 
improved their access criteria with regards to disease severity, 6 with regards to 
sobriety, and 8 with regards to provider specialty.30 Findings from our study indicate that 
these changes are primarily related to lower-than-expected demand, increased market 
competition, and political and legal pressures. While the 2016 report did also find that 
MCOs might have criteria more restrictive than that of the state program, our 
respondents stressed the variability between different MCOs and the lack of 
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transparency in their practices as significant barriers to understanding the coverage 
landscape.  
Respondents indicated regional variation between and within states based on 
geography, economy, and political climate. Access to treating providers in rural areas 
was seen as a challenge even in states where access was not strongly limited by 
insurance requirements. A 2012 study in Wisconsin showed that of 72 counties, 51 had 
no infectious diseases or gastroenterology providers, potentially limiting HCV 
treatment.37 Research in other, related disease states also supports this finding: rural 
Americans may have poorer access to substance use treatment,38 HIV treatment,39and 
preventive care services40 than those in urban areas. This finding is especially relevant 
for HCV given the ongoing rural epidemic related to injection drug use.5, 6 Efforts to 
address this, including using telemedicine to augment access to specialty consultation 
can be successful, but require a public commitment to public health infrastructure in 
order to be implemented.41  If new federal initiatives reduce or restructure funding to 
Medicaid programs, the burden on state budgets may increase, and other patient 
populations may be prioritized for limited resources.  
In all states, individuals co-infected with HIV/HCV have better access to DAA 
treatments than mono-infected individuals and many of our respondents have 
experience working in the field of HIV. While some have called for a response to HCV 
that mimics ADAPs for HIV, this is unlikely to be forthcoming in the current political 
climate.42  Despite this, states can leverage a robust HIV treatment infrastructure in 
order to promote policies that focus on HCV treatment by utilizing existing links between 
public health officials and providers. For examples, epidemiologic surveillance 
strategies used for HIV, such as the cascade of care model, has been applied to 
HCV.43-45 Coordinated care delivery models that are effective in HIV can also be applied 
 15  
to patients with HCV, such as patient navigation to improve linkage to care,46-48 and 
integration of primary care providers to improve treatment capacity.49-52 
Our study has a number of limitations. We selected diverse states based on their 
geography, features of their health systems, and HCV treatment policies to solicit a 
range of perspectives, but with a qualitative sampling design the findings should not be 
interpreted as the average response. Within each state, we recruited primarily 
individuals whose jobs were focused on treatment access, and who were inclined to 
promote treatment access in their own jurisdictions. Further research with individuals 
whose jobs involve allocating state resources may reveal different results. Our 
respondents’ own uncertainties about price negotiations suggests that further work is 
needed to explore the true costs of HCV therapy to different payers. We attempted to 
minimize bias in data interpretation by having two investigators independently code 
interview transcripts and ongoing project meetings to discuss the codebook and results. 
Finally, some of our interviews took place before the 2016 U.S. presidential election, 
and others after. Proposed changes in federal health policy surrounding the change in 
administration may have affected the views of study respondents differently before 
versus after the election.  
Eliminating the HCV epidemic will take a concerted effort from public health and 
healthcare infrastructure. While overcoming the price barrier is necessary, our findings 
show that it is not sufficient. Growing the provider workforce in high need areas and 
resolving urban-rural disparities in access to care will be important steps for treatment 
scale up. The stigma surrounding HCV and substance use is a barrier to informed policy 
and care that must be addressed at the level of patients, providers, health systems, and 
governments. Finally, all of this must be built on a bedrock of healthcare access, a 
continued challenge in today’s U.S. policy environment. The committed, multi-level 
response to the HIV epidemic that has evolved over the past thirty years can serve as 
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an example for the response to HCV. While our study detailed many challenges, it was 
clear that the therapeutic innovations of the past few years have given us an opportunity 
to halt an epidemic that is poised to affect millions. 
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APPENDIX 
Interview guide: 
Introductory questions: 
  First, I would like to ask you some general questions about your position and your 
experience with this issue. 
1. What is your current position within your program/organization?  
2. How long have you been involved with this program/organization? 
3. Can you describe your role in the context of hepatitis C treatment access and 
utilization? 
Mechanisms for HCV DAA acquisition in your state or region 
As you know, new medications for the treatment of hepatitis C are becoming available. 
These medications are very effective, but they can be difficult for some patients to 
obtain because of expense. I would like to explore your experience with this issue. 
 
4. What are the mechanisms that patients in [state/region] have available for accessing 
treatment to hepatitis C? 
a. Specifically patients on Medicaid, if not mentioned 
b. Any planned or innovative programs at the state or local level? 
c. Any specific differences by subpopulation: for instance HIV infected or 
injection drug users 
 
5. Can you discuss any recent or planned policy changes regarding providing access 
to HCV medications for patients enrolled in Medicaid? In other insurance programs? 
a. What are the factors that led to these policies being implemented? 
b. What were the barriers to putting these policies in to place? 
 
6. Have there been any discussion or action regarding adding new HCV medications to 
public insurance formularies (Medicaid, ADAP if applicable)? If so, can you 
describe? 
Barriers to DAA acquisition in your state or region 
7. What are the biggest barriers that patients in [state/region] face for accessing HCV 
treatment? 
a. Specifically for patients on Medicaid, if not mentioned 
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b. Specifically re: drug pricing, provider availability, insurance status if not 
mentioned 
 
8. Many insurance plans have specific authorization requirements that patients must 
meet before obtaining HCV treatment (example: fibrosis status, substance use 
abstinence, provider specialty, HIV viral load suppression, treatment readiness). Can 
you describe how these authorization requirements affect treatment access in 
[state/region]? 
a. Ask about specific requirements if not mentioned 
b. Any recent changes or plans to change, and if so, what motivated the 
changes? 
c. Are requirements consistent across insurance plans? (Medicaid vs managed 
Medicaid vs commercial, Medicare, etc) 
 
9. How would you describe HCV treatment uptake or utilization in [state/region], aside 
from medication access? What are the other barriers to treatment uptake? 
Contrast of the HCV/HIV coinfected population to HCV monoinfected population 
10. Can you discuss any differences in obtaining HCV treatment for the HIV coinfected 
population compared to the HCV monoinfected population? 
a. If not mentioned, ask specifically about ADAP programs, treatment eligbility 
criteria, provider availability 
Additional factors (if not already covered) and future vision 
11. Does your program interact with consumer or patient advocacy groups? What role, 
if any, has advocacy played in HCV treatment access in [state/region]? 
 
12. What role, if any, have recent lawsuits and judicial decisions played in HCV 
treatment access in [state/region]? 
 
13. What role, if any, has federal government and professional society guidance played 
in HCV treatment access in [state/region]? 
 
14. What are your expectations regarding how state programs in general, and yours in 
particular, will respond in the future to the challenge of providing HCV treatment 
access? 
Closing 
Do you have any other comments on the topics that we discussed? 
Is there anyone else that you think we should talk to about the issue of obtaining 
hepatitis C medications for HIV infected patients?  
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It’s possible that as I continue to interview people, new questions might come up. Is it 
okay if I get back to you, via email, if any new questions do arise? 
 
List of Codes 
Factors:  
Administrative barriers–Code prior authorizations, lengthy approval process, other non-
financial non-medical barriers to treatment.  
Advocacy Work – code referring to community advocates, lobbying, etc. 
Cost of treatment – Code related to drug cost (for patients, insurers, govt, etc), drug 
pricing mechanisms, coupons, rebates, etc  
Disease Exceptionalism – Code refers to special policy/political/financial attention given 
to a specific disease, e.g. HIV infected.  
Guidelines - referring to AASLD/IDSA treatment guidelines 
Innovative solutions – use when a respondent mentions an idea or solution that they 
have heard of, e.g. rebates, carve-outs, centers of excellence, health homes, provider 
training, etc 
Legal Factors - Code at mention of any of the lawsuits or legal challenges to treatment 
restrictions 
Medical Eligibility Criteria 
Fibrosis – Code fibrosis stage or general “disease severity” criteria 
Treatment specialty – Code need for specific specialty to give treatment, also 
difficulty accessing said specialties.  
Abstinence – Code need for substance use abstinence including provider 
documentation, treatment engagement, and urine toxicology testing 
HIV treatment/ suppression – Code need for HIV treatment or viral load 
suppression for HIV/HCV coinfected patients  
Treatment Readiness – Code general references to “treatment readiness” or 
concerns about ensuring adherence before starting treatment 
Patient Assistance Programs – Code pharma company funded assistance programs 
Policy Creation Process -- code if someone is describing the process for policy changes 
Political Environment – code when someone is talking about political motivation for 
changes, or political reluctance for change 
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Stigma – code when someone mentions stigma by name or discrimination vis a vis HCV 
infected populations  
Transparency – Code refer to transparency by name, or general difficulty accessing 
information from gov’t, insurance, or drug companies that is perceived to be 
important/necessary information by the participant 
Treatment Uptake – Code when subject refers to treatment uptake  
Factors, NOS – Other factors, passages, or themes that may be interesting but not 
specified above 
Stakeholders, their motivations and their interactions: 
Public Insurance – code at Medicare, Medicaid, ADAP 
Private insurance- code at mention of commercial insurance 
Government – code at federal or state government response, policies, guidance, etc  
Healthcare system / infrastructure – code related to health systems – e.g. HIV program 
infrastructure, substance use treatment programs, academic medical centers, etc 
Patients – Code related to patients or patient subgroups. Child code for HIV infected 
HIV Coinfected – Code related to HIV/HCV coinfected patients 
Media – code related to media pressure 
Pharmaceutical Companies 
Cooperation between stakeholders - code when someone talks about negotiations, 
communication, or cooperative tactics between players 
Conflict between stakeholders – code when someone talks about negative interactions 
between stakeholders 
Stakeholders, NOS – new major actors or stakeholders that are mentioned but are not 
listed above 
Miscellaneous: 
Participant Introductions – Code the response to the “Who are you and what do you do” 
question 
Future predictions – include speculation about the future, hopes, fears, planned 
interventions 
Interesting Quotes  
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